Lyell reports 40% ORR in TNBC from Phase 1 LYL797; expands into ovarian cancer

Lyell Immunopharma, Inc.

ORR of 40% and CBR of 60% at 150e6 CAR T dose in relapsed/refractory TNBC (n=5).
No dose-limiting toxicities in patients without lung involvement; pneumonitis managed with prophylactic steroids.
CAR T cells enhanced with anti-exhaustion technology showed expansion, infiltration, and persistence in solid tumors.
Trial expanded to ROR1+ ovarian/endometrial cancer; new trial for multiple myeloma/CLL planned.
IND submitted for LYL119, next-gen ROR1 CAR T candidate; expected to enter clinic this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.